Pfizer Xinguan oral drug has been approved in domestic emergency conditions, which can reduce the risk of hospitalization / death by 89%

According to the official website of the State Food and drug administration, on February 11, the State Food and Drug Administration approved the import registration of Pfizer's covid-19 / ritonavir tablets combined packaging (paxlovid) in the form of emergency review and approval.

Paxlovid is an oral small molecule covid-19-covid-19-covid-covid-covid-covid-covid-covid-19-covid-covid-covid-19-covid-covid-19-covid-covid-19-covid-19-covid-19-covid-19-covid-19-covid-19-covid-19-covid-19 is. It is also the first oral antiviral drug authorized by the US Food and drug administration to treat covid-19.
The State Food and Drug Administration stressed that patients should strictly follow the instructions under the guidance of doctors, and pay close attention to the interaction information with other drugs listed in the instructions during use. At the same time, the listing permit holders are also required to continue to carry out relevant research work, complete the conditional requirements within a time limit, and submit follow-up research results in time.
Paxlovid is composed of two main components, namatvir and ritonavir. Among them, nimatvir is a covid-19 3CL protease inhibitor, which can destroy the subsequent RNA replication process of novel coronavirus by blocking the activity of covid-19 3CL protease. Another component, ritonavir, allows namatvir to maintain longer activity in the body and better fight the virus.
On November 5, 2021, Pfizer released the interim analysis results of paxlovid's phase II / III study on its official website, which showed that paxlovid reduced the risk of hospitalization or death by 89%.
Specifically, among patients treated with paxlovid within three days of symptom onset, paxlovid reduced the risk of covid-19 related hospitalization or death from any cause by 89% compared with placebo (primary endpoint). Among patients treated within five days of symptom onset, there was a similar reduction in hospitalization or death associated with covid-19.
It is worth noting that on January 18, 2022, Pfizer further announced the results of paxlovid's in vitro study on the covid-19 variant Omicron. The results showed that paxlovid may be able to maintain the plasma concentration to prevent the continuous replication of Omicron.
On December 23, 2021, paxlovid obtained the emergency use authorization (EUA) issued by FDA to treat mild to moderate covid-19 in adults and children.